Pfizer, XTANDI
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor,
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...
The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
Pfizer's drug combination improves survival in prostate cancer patients. Starboard Value pressures Pfizer over board conduct.
US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback